Renal Cell Carcinoma
Conditions
Interventions
A:Standard non - blocking technique
A:No blocking technique for reserved stitches
A:Preoperative DSA superselective embolization has no blocking technique
A:"2+1" suture technique
C:The molecular expression levels of Mir-497-5P, EIF3D, Gankyrin and RASSF10 were detected in postoperative tumor tissues
D:The biopsy tissues were tested by gene in situ hybridization or single cell transcriptomic sequencing to predict sensitive targeted drugs. The individual renal carcinoma organ model was used to scre
E:therapy according to guide or experience
Sponsors
Department of Urology, The Third Affiliated Hospital of Naval Medical University, PLA
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. To establish a personalized kidney-preserving surgery strategy for early localized renal carcinoma:CTA, MRI imaging examination; renal carcinoma of T1 stage assessed by imaging. Single lesion of unilateral kidney; Ability to sign informed consent; 2. Establish a risk prediction model for postoperative recurrence, metastasis and prognosis of renal carcinoma; The postoperative pathology was renal clear cell carcinoma; There was no other malignant tumor except renal carcinoma; Ability to sign informed consent; 3. Selection of personalized targeted therapies based on gene in situ hybridization, single-cell transcriptomic sequencing and other gene detection technologies:Receive molecular targeted therapy; Biopsy of metastatic or primary lesions was performed; No bone marrow, kidney, liver, heart and other functional impairment before treatment; No prior medical treatment against tumor; Postoperative histology confirmed renal clear cell carcinoma; Ability to sign informed consent.
Exclusion criteria
Exclusion criteria: 1. To establish a personalized kidney-preserving surgery strategy for early localized renal carcinoma;Multiple or bilateral renal tumor lesions; Previous history of renal surgery; Serious cardiovascular and cerebrovascular diseases; Failure of liver, kidney and respiratory function; 2. Establish a risk prediction model for postoperative recurrence, metastasis and prognosis of renal carcinoma; Non-renal clear cell carcinoma; Accompanied by other malignant tumors; Serious cardiovascular and cerebrovascular diseases; Failure of liver, kidney and respiratory function; 3. Selection of personalized targeted therapies based on gene in situ hybridization, single-cell transcriptomic sequencing and other gene detection technologies:Non-renal clear cell carcinoma; Serious cardiovascular and cerebrovascular diseases; Failure of liver, kidney and respiratory function; Patients with previous anti-tumor failures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intraoperative parameters;Postoperative hospitalization parameters;Postoperative follow-up parameters;PFS and OS time;Follow-up parameters after targeted therapy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Major pathology response rate after targeted therapy;Patient satisfaction score;the changes of imaging;biomarkers;the comparison of efficacy of groups; | — |
Countries
China
Contacts
Public ContactCui Xin-gang
Department of Urology, The Third Affiliated Hospital of Naval Medical University, PLA
Outcome results
None listed